Home|Journals|Articles by Year|Audio Abstracts
 

Case Report



Dapsone-induced methemoglobinemia in immune thrombocytopenia: A case report

Chanshi Chandran, Anju A Mathew, Ranjini Pillai, Roshni PR.




Abstract

ITP is a bleeding disorder which is not associated by a systemic disease caused by low platelet count or thrombocytes. However, use of dapsone is limited by adverse effects such as methemoglobinemia, reticulocyte increase, hemolysis, hemoglobin decrease, red cell life span shortened, agranulocytosis, anemia, leukopenia, and pure red cell aplasia. This report relates to an incident to methemoglobinemia after administration of dapsone as the second line agent for treatment of ITP in a tertiary care hospital. A 46-year-old male, with a case of immune thrombocytopenia and a family history of aplastic anemia in mother. Now presented with high grade fever associated with generalized weakness, cough with expectoration and shortness of breath and decreased urine output. He was admitted for further management. Initial laboratory investigations were done. Blood and urine cultures were sent. His arterial blood gas showed elevated methemoglobin (18.2). Peripheral smear revealed microcytic hypochromic anemia with polychromatophils, microspherocytes, and relative neutrophilia. Urine culture showed Escherichia coli and blood culture was sterile. Serum electrolytes were sent. He had elevated international normalized ratio (INR) value (5.93). Warfarin and dapsone were withheld.

Key words: Dapsone; Immune thrombocytopenia; Methemoglobinemia






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.